drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T-cell therapy)
drug_description
An autologous, gene-modified T-cell therapy in which a patient’s peripheral blood T cells are engineered to express a CD19-specific chimeric antigen receptor (anti-CD19 scFv). CAR engagement enables MHC-independent recognition and activation of T-cell effector functions (cytotoxic killing and cytokine release), leading to depletion of CD19+ leukemic and normal B cells in CD19+ B-ALL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor bind CD19 on B cells and trigger MHC-independent T-cell activation, cytotoxic killing, and cytokine release, resulting in depletion of CD19+ leukemic and normal B cells.
drug_name
SNUH-CD19-CAR-T
nct_id_drug_ref
NCT06247501